|
北京看白癜风要多少钱 http://baidianfeng.39.net/bdfby/yqyy/22MarA--Arandomizedcontrolledclinicaltrial,calledDiscoverystartedinEuropeantoevaluatefourexperimentaltreatmentsforCOVID-19startstoday.年3月22日，欧洲宣布开始一项代号“发现”（Discovery）的随机对照研究，评估COVID-19四种实验治疗方法的疗效。ItisledbyFlorenceAder,infectiologistintheInfectiousandTropicalDiseasesDepartmentoftheCroix-RousseHospitalofLyonUniversityHospital.医院CroixRousse医院传染病和热带病科的传染病学家FlorenceAder领导。ItisplannedtoincludeEuropeanpatientsfromBelgium,France,GermanyLuxembourg,theNetherlands,Spain,Sweden,andtheUnitedKingdom.InFrance,atleasthospitalizedCOVID-19patientswillberecruited.该计划包括名来自比利时、法国、德国、卢森堡、荷兰、西班牙、瑞典和英国的欧洲患者，其中法国至少有名住院患者将参加。Thetrialincludesfivetreatmentmodalities:a)standardofcareb)standardofcareplusremdesivirc)standardofcarepluslopinavirandritonavir,d)standardofcarepluslopinavir,ritonavirandinterferonbetae)standardofcareplushydroxy-chloroquine.具体治疗方案和分组如下：1.标准治疗2.标准治疗加remdesivir3.标准治疗加洛匹那韦和利托那韦，4.准治疗加洛匹那韦、利托那韦和β干扰素5.标准治疗加羟基氯喹。Theanalysisoftreatmentefficacyandsafetywillbeevaluated15daysafterinclusionofeachpatient.每个患者治疗15天后将对治疗效果和安全性进行评估。Thegreatstrengthofthistrialisits“adaptive”nature.Thismeansthatineffectiveexperimentaltreatmentscanveryquicklybedroppedandreplacedbyothermoleculesthatemergefromresearchefforts.Wewillthereforebeabletomakechangesinrealtime,inlinewiththemostrecentscientificdata,inordertofindthebesttreatmentforourpatients.这项试验的最大亮点是它的“适应性”。这意味着，无效的治疗方案会马上被放弃，并由不断发现的其他有前景的药物取代，最终找到最佳治疗方案。Thistrialwillalso 转载请注明原文网址：http://www.skomx.com/mbyhl/10867.html |
